175 related articles for article (PubMed ID: 35439353)
41. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
42. Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus.
Lee JT; Whitson BA; Kelly RF; D'Cunha J; Dunitz JM; Hertz MI; Shumway SJ
J Surg Res; 2013 Sep; 184(1):599-604. PubMed ID: 23566442
[TBL] [Abstract][Full Text] [Related]
43. Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients.
Kozuch JM; Burt C; Afshar K; Aslam S; Yung G; Mariski M; Golts E; Feist A
Transpl Infect Dis; 2024 Feb; 26(1):e14209. PubMed ID: 38059638
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[TBL] [Abstract][Full Text] [Related]
45. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience.
Gozdowska J; Urbanowicz AL; Galazka Z; Chmura A; Durlik M
Transplant Proc; 2011 Oct; 43(8):2946-9. PubMed ID: 21996197
[TBL] [Abstract][Full Text] [Related]
46. A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada.
Prasad GV; Nash MM; Keough-Ryan T; Shapiro RJ
J Nephrol; 2010; 23(3):274-81. PubMed ID: 20383867
[TBL] [Abstract][Full Text] [Related]
47. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants.
Undre N; Dickinson J
BMJ Open; 2017 Apr; 7(4):e012252. PubMed ID: 28377389
[TBL] [Abstract][Full Text] [Related]
48. A Joint Pharmacokinetic Model for the Simultaneous Description of Plasma and Whole Blood Tacrolimus Concentrations in Kidney and Lung Transplant Recipients.
Koomen JV; Knobbe TJ; Zijp TR; Kremer D; Gan CT; Verschuuren EAM; Bakker SJL; Touw DJ; Colin PJ;
Clin Pharmacokinet; 2023 Aug; 62(8):1117-1128. PubMed ID: 37306899
[TBL] [Abstract][Full Text] [Related]
49. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
50. Evidence of different pharmacokinetics including relationship among AUC, peak, and trough levels between cyclosporine and tacrolimus in renal transplant recipients using new pharmacokinetic parameter--why cyclosporine is monitored by C(2) level and tacrolimus by trough level--.
Takeuchi H; Matsuno N; Senuma K; Hirano T; Yokoyama T; Taira S; Kihara Y; Kuzuoka K; Konno O; Jojima Y; Mejit A; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Ashizawa T; Nagao T; Toraishi T; Okuyama K; Oka K; Unezaki S
Biol Pharm Bull; 2008 Jan; 31(1):90-4. PubMed ID: 18175948
[TBL] [Abstract][Full Text] [Related]
51. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors.
Bardet V; Junior AP; Coste J; Lecoq-Lafon C; Chouzenoux S; Bernard D; Soubrane O; Lacombe C; Calmus Y; Conti F
Liver Transpl; 2006 Nov; 12(11):1649-54. PubMed ID: 17058250
[TBL] [Abstract][Full Text] [Related]
52. Clinical Pharmacokinetics and Bayesian Estimators for the Individual Dose Adjustment of a Generic Formulation of Tacrolimus in Adult Kidney Transplant Recipients.
Marquet P; Destère A; Monchaud C; Rérolle JP; Buchler M; Mazouz H; Etienne I; Thierry A; Picard N; Woillard JB; Debord J
Clin Pharmacokinet; 2021 May; 60(5):611-622. PubMed ID: 33230714
[TBL] [Abstract][Full Text] [Related]
53. Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase.
Mino Y; Naito T; Otsuka A; Takayama T; Ozono S; Kagawa Y; Kawakami J
J Clin Pharm Ther; 2011 Apr; 36(2):217-24. PubMed ID: 21366651
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
McCrea JB; Macha S; Adedoyin A; Marshall W; Menzel K; Cho CR; Liu F; Zhao T; Levine V; Kraft WK; Yoon E; Panebianco D; Stoch SA; Iwamoto M
J Clin Pharmacol; 2019 Oct; 59(10):1331-1339. PubMed ID: 30990905
[TBL] [Abstract][Full Text] [Related]
55. Early Postoperative Kidney Transplant Complications Related to Immunomodulator Regimen in Pediatric Recipients.
Noorbakhsh S; Rahimzadeh N; Hosseini R; Otookesh H; Ehsanpoor F; Aminpour Y
Exp Clin Transplant; 2022 Jul; 20(7):663-667. PubMed ID: 35924744
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
[TBL] [Abstract][Full Text] [Related]
57. The effect of maintenance immunosuppression medication on the change in kidney allograft function.
Gill JS; Tonelli M; Mix CH; Johnson N; Pereira BJ
Kidney Int; 2004 Feb; 65(2):692-9. PubMed ID: 14717943
[TBL] [Abstract][Full Text] [Related]
58. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
Takeuchi H; Matsuno N; Hirano T; Toraishi T; Konno O; Nakamura Y; Iwamoto H; Hama K; Unezaki S; Nagao T
Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
[TBL] [Abstract][Full Text] [Related]
59. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
[TBL] [Abstract][Full Text] [Related]
60. Calcineurin inhibitors in pediatric renal transplant recipients.
Filler G
Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
